Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

About this update from Aptorum Group Limited

[{"type":"text","content":"NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens” in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research.","length":690,"tagName":"p"},{"type":"text","content":"This study, conducted in collaboration with clinical researchers at the Perelman School of Medicine at the University of Pennsylvania, demonstrates the feasibility of detecting glioblastoma (GBM) — the most aggressive and lethal form of brain cancer — through a minimally invasive blood plasma test. The research identifies specific microRNA signatures in blood plasma that show significant promise as non-invasive biomarkers for glioblastoma diagnosis and monitoring.","length":468,"tagName":"p"},{"type":"text","content":"GBM is among the deadliest of all human cancers, with a median survival of fewer than 15 months following diagnosis. Current diagnostic approaches rely on invasive surgical biopsies or costly imaging procedures. DiamiR’s microRNA platform represents a potential paradigm shift, one that we believe will enable earlier detection and improve patient monitoring through a simple blood draw.","length":387,"tagName":"p"},{"type":"text","content":"According to Alidad Mireskandari, Ph.D., Chief Executive Officer of DiamiR, “We are proud to announce the publication of our latest peer-reviewed data demonstrating the clinical potential of microRNA biomarkers in the detection of glioblastoma. This work builds on a growing body of evidence supporting the role of microRNAs in Brain Health and represents an important validation of our platform. I’m grateful to our team and collaborators at The University of Pennsylvania Perelman School of Medicine for their thoughtful work behind this publication. Glioblastoma remains an incredibly challenging disease, and I hope this work adds constructively to the b...

More updates from Aptorum Group Limited